Amphastar Pharmaceuticals, Inc. 8K

Amphastar Pharmaceuticals reported Q2 2026 results with modest revenue growth, solid profitability, a significant BAQSIMI sales milestone triggering a $100 million payment to Eli Lilly, and continued investment in its product pipeline.

On August 6, 2026, Amphastar Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2026, announcing net revenues of $183.9 million (up 5% year over year), GAAP net income of $30.3 million or $0.67 per diluted share, and adjusted non-GAAP net income of $40.8 million or $0.91 per diluted share, driven by growth in recently launched higher-margin products such as iron sucrose, teriparatide, and ipratropium bromide, alongside a product mix shift including softer pricing and volumes in BAQSIMI, Primatene MIST, epinephrine multi-dose vials, and glucagon; the company also disclosed achieving a $175.0 million BAQSIMI contract-year sales milestone that will trigger a $100.0 million payment to Eli Lilly in Q3 2026, provided an update on its generic, biosimilar, and proprietary development pipeline, and announced a same-day investor conference call to discuss these results.

Filing Facts

CIK

1297184

Ticker

AMPH

Form

8K

Source Type

fda

Accession

0001297184-26-000045

Alert Tier

6